Skip to main content

Table 1 Identification of potential HLA-A2.1-restricted CTL epitopes from ECM1

From: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine

Epitope

Start

End

Length

Sequence

IC50 (nM)a

S valueb

NP

168

176

9

PPGRPSPDN

46,882.04

− 11.09

KA

90

98

9

KLLPAQLPA

15

− 36.26

YV

488

496

9

YLSPGDEQV

18.15

− 34.22

IV

409

417

9

ILTIDISRV

102.40

− 38.65

AV

8

16

9

ALVLTYLAV

174.81

− 39.46

YL

43

51

9

YAAPPSPPL

267.8

− 40.34

LA

9

17

9

LVLTYLAVA

334.48

− 42.45

QP

86

94

9

LQQEKLLPA

392.06

− 41.10

  1. aIC50, the half maximal inhibitory concentration, obtained from IEDB, IC50 < 500 nM
  2. bS value, the free-energy between docking molecules calculated by MOE